NovaBay Pharmaceuticals, Inc. NBY, a biopharmaceutical company
focusing on the development and commercialization of its non-antibiotic
anti-infective products, today announced that its partner China Pioneer Pharma
Holdings, Limited (HK Stock Code:1345), a leading marketer of branded
pharmaceutical products and medical devices in China, has placed its first
order for NovaBay's NeutroPhase^® Skin and Wound Cleanser. NovaBay will be
shipping NeutroPhase to China later this year to support Pioneer's launch of
the product in early 2015 throughout mainland China.
The order follows the clearance in early September of NeutroPhase for sale in
China by China's Food and Drug Administration.
“We believe that China will be a significant market for NeutroPhase because
the product has the potential to bring a major improvement in medical care in
China,” said Dr. Ron Najafi, Chairman and CEO of NovaBay.
NeutroPhase offers new options for managing both the chronic wounds of
diabetes patients and for deadly flesh-eating disease (necrotizing fasciitis).
China is now experiencing what experts call a ‘catastrophic' epidemic of
diabetes. According to estimates provided by the International Diabetes
Federation and the American Medical Association, approximately 100 million
Chinese already suffer from this condition and from the side effects of
diabetes, such as diabetic ulcers and other chronic wounds. NeutroPhase is
ideally formulated for the management of these types of wounds and many others
such as venous stasis ulcers and pressure ulcers that can seriously affect a
patient's morbidity and mortality.
NovaBay's FDA-cleared NeutroPhase has shown remarkable properties in the
management of these categories of wounds. As John Crew, M.D., FACS states in
the peer-reviewed International Journal of Burns and Trauma, “Patients showed
a profound improvement and marked accelerated rates of wound healing using
NeutroPhase with and without NPWT (negative pressure wound therapy).
NeutroPhase was non-toxic to living tissues.”
NeutroPhase contains a substance produced naturally by the immune system as a
first defense against microbial invaders. Laboratory tests show that
NeutroPhase not only kills bacteria that infect wounds and cause necrotizing
fasciitis, it also neutralizes toxins produced by both bacteria and the immune
system that impede healing and destroy healthy tissue. Those properties enable
NeutroPhase to address acute infections and to help promote the healing of
chronic wounds.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in